Inozyme announces interim data from its ENERGY 1 trial, EAP on INZ-701

Inozyme (INZY) Pharma announced positive interim data from its ENERGY 1 trial and Expanded Access Program, EAP, evaluating INZ-701 in infants and young children with ENPP1 Deficiency, completion of enrollment in the ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency and regulatory guidance for the ASPIRE pivotal trial in children with ABCC6 Deficiency. Key results include: improved survival; reduction in Arterial Calcifications; improved heart function; reduced risk of rickets; favorable safety profile